Daniel S. Levine
@dslevine.bsky.social
Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.
Anita Modi, CEO and founder of Peer AI, discusses the cultural challenges of integrating AI into a traditionally cautious industry, the need for change management, and why it’s critical to embed human judgment alongside machine intelligence.
www.agilisium.com/podcast/agen...
www.agilisium.com/podcast/agen...
Agents of Change: Creating Regulatory Documents with AI
In this episode of Life Sciences DNA, Srivatsan Nagaraja speaks with Anita Modi, Founder and CEO of Peer AI, about how agentic AI is reshaping the creation of regulatory and clinical documents across ...
www.agilisium.com
November 27, 2025 at 5:45 PM
Anita Modi, CEO and founder of Peer AI, discusses the cultural challenges of integrating AI into a traditionally cautious industry, the need for change management, and why it’s critical to embed human judgment alongside machine intelligence.
www.agilisium.com/podcast/agen...
www.agilisium.com/podcast/agen...
Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.
thebioreport.podbean.com/e/rewriting-...
thebioreport.podbean.com/e/rewriting-...
November 26, 2025 at 3:58 PM
Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.
thebioreport.podbean.com/e/rewriting-...
thebioreport.podbean.com/e/rewriting-...
Nikki McIntosh, author of “Rare Mamas: Empowering Strategies for Navigating Your Child’s Rare Disease,” discusses her new book, the challenges faced by rare disease families, and the importance of making time for self-care. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/na...
globalgenes.org/raredaily/na...
Navigating Your Child’s Rare Disease
Nikki McIntosh, author of “Rare Mamas: Empowering Strategies for Navigating Your Child’s Rare Disease,” discusses her new book, the medical, emotional, and logistical challenges faced by rare disease ...
globalgenes.org
November 21, 2025 at 3:56 PM
Nikki McIntosh, author of “Rare Mamas: Empowering Strategies for Navigating Your Child’s Rare Disease,” discusses her new book, the challenges faced by rare disease families, and the importance of making time for self-care. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/na...
globalgenes.org/raredaily/na...
Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
November 19, 2025 at 4:45 PM
Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
Andrew Rosen @ataxiafoundation.bsky.social, discusses the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ch...
globalgenes.org/raredaily/ch...
Changing a Treatment Landscape by De-Risking Drug Development
Andrew Rosen, CEO of the National Ataxia Foundation, discusses the challenges of developing therapies for spinocerebellar ataxia, the critical role of patient-led organizations in early-stage research...
globalgenes.org
November 14, 2025 at 5:02 PM
Andrew Rosen @ataxiafoundation.bsky.social, discusses the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ch...
globalgenes.org/raredaily/ch...
Ronel Veksler, co-founder and CEO of PromiseBio discusses his company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases. www.youtube.com/watch?v=jeJh...
Redefining Biomarkers for Immune-Mediated Disease with AI
YouTube video by Life Sciences DNA Podcast
www.youtube.com
November 13, 2025 at 7:02 PM
Ronel Veksler, co-founder and CEO of PromiseBio discusses his company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases. www.youtube.com/watch?v=jeJh...
Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.
thebioreport.podbean.com/e/a-hub-and-...
thebioreport.podbean.com/e/a-hub-and-...
November 12, 2025 at 2:56 PM
Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.
thebioreport.podbean.com/e/a-hub-and-...
thebioreport.podbean.com/e/a-hub-and-...
Jeffrey Brown CSO of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI could revolutionize rare disease research. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/tr...
globalgenes.org/raredaily/tr...
Transforming Real-Word Patient Data into Breakthroughs
Jeff Brown, chief scientific officer of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI cou...
globalgenes.org
November 7, 2025 at 5:15 PM
Jeffrey Brown CSO of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI could revolutionize rare disease research. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/tr...
globalgenes.org/raredaily/tr...
Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold.
thebioreport.podbean.com/e/an-ai-coll...
thebioreport.podbean.com/e/an-ai-coll...
November 5, 2025 at 3:24 PM
Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold.
thebioreport.podbean.com/e/an-ai-coll...
thebioreport.podbean.com/e/an-ai-coll...
Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
www.linkedin.com/pulse/why-us...
www.linkedin.com/pulse/why-us...
Why the U.S. Must Fall in Love with Biotech, Rare Disease Advocates Push FDA for Timely Reviews, and Driving Insights from Real-World Data and AI
Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report Hitting the Reset Button on Cellular Aging Transcription factors control the ...
www.linkedin.com
November 3, 2025 at 8:51 PM
Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
www.linkedin.com/pulse/why-us...
www.linkedin.com/pulse/why-us...
Prarthana Khanna, VP of corporate business development and strategy for Vico Therapeutics, discusses Huntington's disease, the company’s experimental ASO, and why it has the potential to address multiple neurological diseases. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ta...
globalgenes.org/raredaily/ta...
Taking Aim at Huntington’s Disease and Other Repeat Expansion Disorders
Prarthana Khanna, vice president of corporate business development and strategy for Vico, discusses Huntington's disease, the company’s experimental ASO to target the disease, and why it has the poten...
globalgenes.org
October 31, 2025 at 2:39 PM
Prarthana Khanna, VP of corporate business development and strategy for Vico Therapeutics, discusses Huntington's disease, the company’s experimental ASO, and why it has the potential to address multiple neurological diseases. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ta...
globalgenes.org/raredaily/ta...
John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity.
thebioreport.podbean.com/e/hitting-th...
thebioreport.podbean.com/e/hitting-th...
October 29, 2025 at 3:10 PM
John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity.
thebioreport.podbean.com/e/hitting-th...
thebioreport.podbean.com/e/hitting-th...
Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community and her own voice as an advocate. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/le...
globalgenes.org/raredaily/le...
Learning to Be a Caregiver and Advocate
Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community of supp...
globalgenes.org
October 24, 2025 at 3:04 PM
Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community and her own voice as an advocate. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/le...
globalgenes.org/raredaily/le...
Aaron Cohen, Head of Research Oncology, Clinical Data at Flatiron Health, joins Amar Drawid, on Life Sciences DNA to explore how large language models are transforming oncology research.
www.youtube.com/watch?v=W-Gq...
www.youtube.com/watch?v=W-Gq...
Driving Insights from Real World Oncology Data with AI
YouTube video by Life Sciences DNA Podcast
www.youtube.com
October 23, 2025 at 7:59 PM
Aaron Cohen, Head of Research Oncology, Clinical Data at Flatiron Health, joins Amar Drawid, on Life Sciences DNA to explore how large language models are transforming oncology research.
www.youtube.com/watch?v=W-Gq...
www.youtube.com/watch?v=W-Gq...
Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.
thebioreport.podbean.com/e/changing-t...
thebioreport.podbean.com/e/changing-t...
October 22, 2025 at 2:23 PM
Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.
thebioreport.podbean.com/e/changing-t...
thebioreport.podbean.com/e/changing-t...
The Rwanda FDA approved @BioUsawa 's BioUcenta, a biosimilar of Lucentis. It is the first biosimilar ranibizumab approved in Africa and represents the first major regulatory milestone for Bio Usawa.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
BioUcenta™ is the first biosimilar of Lucentis (ranibizumab) approved in Africa...
www.globenewswire.com
October 20, 2025 at 8:43 PM
The Rwanda FDA approved @BioUsawa 's BioUcenta, a biosimilar of Lucentis. It is the first biosimilar ranibizumab approved in Africa and represents the first major regulatory milestone for Bio Usawa.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Laura Russo, U.S. patient engagement lead for Pfizer, discusses how the company’s patient-facing teams work to bridge health systems and patient communities to improve access and care. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/im...
globalgenes.org/raredaily/im...
Improving Rare Disease Care through Partnerships
Laura Russo, U.S. patient engagement lead for Pfizer, discusses how the company’s patient-facing teams work to bridge health systems and patient communities, how they help people with rare diseases na...
globalgenes.org
October 17, 2025 at 2:44 PM
Laura Russo, U.S. patient engagement lead for Pfizer, discusses how the company’s patient-facing teams work to bridge health systems and patient communities to improve access and care. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/im...
globalgenes.org/raredaily/im...
Drew Endy, senior fellow of the Hoover Institution, discusses China’s all-of-nation strategy, how the United States has misallocated research dollars, and why a cultural embrace of biotechnology will be critical for the success of either country.
thebioreport.podbean.com/e/why-the-un...
thebioreport.podbean.com/e/why-the-un...
Why the United States Must Fall in Love with Biotechnology, or Take a Back Seat to China | The Bio Report
China’s emergence as a biotech superpower may have appeared to happen suddenly, but it reflected a long-term vision and policies over many years that enabled its success. As biotechnology transforms n...
thebioreport.podbean.com
October 15, 2025 at 2:59 PM
Drew Endy, senior fellow of the Hoover Institution, discusses China’s all-of-nation strategy, how the United States has misallocated research dollars, and why a cultural embrace of biotechnology will be critical for the success of either country.
thebioreport.podbean.com/e/why-the-un...
thebioreport.podbean.com/e/why-the-un...
Kristin McKay, CEO of Project Alive, discusses the need for new therapies for Hunter syndrome, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/a-...
globalgenes.org/raredaily/a-...
A Call on the FDA for Timely Reviews of Life-Saving Therapies for Rare Diseases
Kristin McKay, CEO of the Hunter syndrome patient advocacy organization Project Alive, about the need for new therapies, the importance of early detection, and the patient community’s concerns with re...
globalgenes.org
October 10, 2025 at 2:33 PM
Kristin McKay, CEO of Project Alive, discusses the need for new therapies for Hunter syndrome, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/a-...
globalgenes.org/raredaily/a-...
Arc Institute’s Hani Goodarzi, Ultima Genomics' Gilad Almogy, and 10X Genomics' Serge Saxonov discuss the ARC Virtual Cell Atlas, which uses single-cell genomics, AI, and open science to understand the complexities of cellular behavior.
thebioreport.podbean.com/e/transformi...
thebioreport.podbean.com/e/transformi...
Transforming Drug Discovery and Disease Research—One Cell at a Time | The Bio Report
The ARC Virtual Cell Atlas uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. Developed through a partnership bet...
thebioreport.podbean.com
October 8, 2025 at 2:28 PM
Arc Institute’s Hani Goodarzi, Ultima Genomics' Gilad Almogy, and 10X Genomics' Serge Saxonov discuss the ARC Virtual Cell Atlas, which uses single-cell genomics, AI, and open science to understand the complexities of cellular behavior.
thebioreport.podbean.com/e/transformi...
thebioreport.podbean.com/e/transformi...
Amélie Lothe, global medical community head for rare epilepsies at UCB, discusses the importance of looking beyond seizures to view developmental and epileptic encephalopathies as complex neurodevelopmental conditions. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/th...
globalgenes.org/raredaily/th...
The Need to Look Beyond Seizures When Treating DEEs
Amelie Lothe, global medical community head for rare epilepsies at UCB, about the importance of viewing developmental and epileptic encephalopathies as complex neurodevelopmental conditions, the need ...
globalgenes.org
October 3, 2025 at 5:19 PM
Amélie Lothe, global medical community head for rare epilepsies at UCB, discusses the importance of looking beyond seizures to view developmental and epileptic encephalopathies as complex neurodevelopmental conditions. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/th...
globalgenes.org/raredaily/th...
Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward.
thebioreport.podbean.com/e/scratching...
thebioreport.podbean.com/e/scratching...
October 1, 2025 at 2:07 PM
Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward.
thebioreport.podbean.com/e/scratching...
thebioreport.podbean.com/e/scratching...
Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
www.linkedin.com/pulse/extend...
www.linkedin.com/pulse/extend...
Extending the Life of Transplanted Kidneys, Changing the Playbook on Childhood Cancers, and Navigating AI in Clinical Development
Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report A Dual Action Approach to Treating MASH MASH, a chronic and progressive for...
www.linkedin.com
September 30, 2025 at 3:04 PM
Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
www.linkedin.com/pulse/extend...
www.linkedin.com/pulse/extend...
Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ta...
globalgenes.org/raredaily/ta...
Taking On Big Competitors with an Oral Therapy to Treat Achondroplasia
Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental once-daily, oral medicine for achondroplasia; what’s known about it from studies conducted to date, and why he believes it wi...
globalgenes.org
September 26, 2025 at 4:16 PM
Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/ta...
globalgenes.org/raredaily/ta...
What happens when AI touches every role, every day, in clinical development? Stephen Pyke of @parexel.bsky.social, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential.
trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s
trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s
September 25, 2025 at 3:05 PM
What happens when AI touches every role, every day, in clinical development? Stephen Pyke of @parexel.bsky.social, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential.
trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s
trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s